Biostem Technologies (BSEM) Q1 2026 earnings summary

Executive summary

• Completed a transformative acquisition in January 2026, integrating BioTissue surgical and wound care assets, expanding the sales force to 35 representatives, and shifting focus from physician office to hospital channel, broadening the addressable market with new products and GPO contracts.

• Integration of acquired assets has been smooth, with minimal disruption and stable sales performance in the hospital business.

• Strategic priorities include integrating the acquisition, scaling the sales force, advancing the product roadmap, and executing a technology transfer for key products.

• Confidentially submitted Form 10 to the SEC and issued audited financials for 2024 and 2025, aiming for a Nasdaq uplisting to enhance visibility and access to capital.

• Retired $3 million in principal and $2.3 million in accrued interest debt with GMA, and appointed a new Chief Legal and Compliance Officer.

Financial highlights

• Q1 2026 revenue was $6.1 million, above guidance of $5–$6 million, but down from $10.1 million in the prior quarter and $16.0 million in Q1 2025.

• Hospital revenue was $5.4 million (87% of total); physician office revenue was $772,000.

• Gross profit was $3.8 million (61% margin), down from $9.8 million (97%) in the prior period due to product mix and supply agreement terms.

• Operating expenses were $12.6 million, down from $17.3 million sequentially, but up from $9.9 million in Q1 2025, reflecting lower bad debt but higher acquisition and uplisting costs.

• GAAP net loss was ($8.8 million) or ($0.52) per share, versus net income of $3.9 million or $0.23 per share in Q1 2025.

Outlook and guidance

• Initiated 2026 revenue guidance of $25–$29 million, reflecting integration progress and hospital market focus.

• Sequential revenue growth expected each quarter, with Q2 as the first full quarter post-acquisition and stronger growth anticipated in the second half of 2026.

• Margin expansion expected after technology transfer in 2027, targeting well above 60% gross margin.

• Physician office market expected to stabilize and return to sequential revenue growth in H2 2026.